Related Experiment Video
Updated: Jul 23, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeting Prostate Cancer, the 'Tousled Way'
Siddhant Bhoir1, Arrigo De Benedetti1
1Department of Biochemistry and Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA.
Abstract:
Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis. Resistance to ADT arises through various mechanisms, and most castration-resistant PCas still rely on the androgen axis, while others become truly androgen receptor (AR)-independent. Our research identified the human tousled-like kinase 1 (TLK1) as a crucial early mediator of PCa cell adaptation to ADT, promoting androgen-independent growth, inhibiting apoptosis, and facilitating cell motility and metastasis. Although explicit, the growing role of TLK1 biology in PCa has remained underrepresented and elusive. In this review, we aim to highlight the diverse functions of TLK1 in PCa, shed light on the molecular mechanisms underlying the transition from androgen-sensitive (AS) to an androgen-insensitive (AI) disease mediated by TLK1, and explore potential strategies to counteract this process. Targeting TLK1 and its associated signaling could prevent PCa progression to the incurable metastatic castration-resistant PCa (mCRPC) stage and provide a promising approach to treating PCa.
Insights
Human tousled-like kinase 1 (TLK1) drives prostate cancer (PCa) adaptation to androgen deprivation therapy (ADT). Targeting TLK1 may prevent progression to incurable metastatic castration-resistant PCa (mCRPC).
Area of Science:
- Oncology
- Molecular Biology
- Prostate Cancer Research
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer (PCa).
- Resistance to ADT leads to castration-resistant PCa (CRPC), often with poor prognosis.
- Mechanisms of ADT resistance include androgen receptor (AR)-dependent and -independent pathways.
Purpose of the Study:
- To identify key mediators of PCa adaptation to ADT.
- To elucidate the role of human tousled-like kinase 1 (TLK1) in PCa progression.
- To explore TLK1 as a therapeutic target for advanced PCa.
Main Methods:
- Identification of TLK1 as a mediator of PCa cell adaptation to ADT.
- Analysis of TLK1's role in promoting androgen-independent growth, apoptosis inhibition, and metastasis.
- Review of existing literature on TLK1 biology in PCa.
Main Results:
- TLK1 is identified as a crucial early mediator in PCa cell adaptation to ADT.
- TLK1 promotes androgen-independent growth and facilitates cell motility and metastasis.
- TLK1 plays a significant role in the transition from androgen-sensitive to androgen-insensitive PCa.
Conclusions:
- TLK1 is a key driver of resistance to androgen deprivation therapy in prostate cancer.
- Targeting TLK1 signaling may offer a novel strategy to prevent progression to metastatic castration-resistant PCa (mCRPC).
- Further research into TLK1 inhibitors could provide new therapeutic avenues for treating advanced PCa.
